JP2012505896A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012505896A5 JP2012505896A5 JP2011532190A JP2011532190A JP2012505896A5 JP 2012505896 A5 JP2012505896 A5 JP 2012505896A5 JP 2011532190 A JP2011532190 A JP 2011532190A JP 2011532190 A JP2011532190 A JP 2011532190A JP 2012505896 A5 JP2012505896 A5 JP 2012505896A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- alkenyl
- compound according
- compound
- heterocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 168
- 125000000217 alkyl group Chemical group 0.000 claims 130
- 125000003342 alkenyl group Chemical group 0.000 claims 85
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 58
- 125000000623 heterocyclic group Chemical group 0.000 claims 33
- 125000005842 heteroatom Chemical group 0.000 claims 19
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 18
- 229910052760 oxygen Inorganic materials 0.000 claims 16
- 201000010099 disease Diseases 0.000 claims 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 14
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 claims 13
- 125000000753 cycloalkyl group Chemical group 0.000 claims 13
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 12
- 208000017169 kidney disease Diseases 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 239000000126 substance Substances 0.000 claims 10
- 125000001424 substituent group Chemical group 0.000 claims 10
- 229910052717 sulfur Inorganic materials 0.000 claims 9
- 125000003118 aryl group Chemical group 0.000 claims 8
- 125000001072 heteroaryl group Chemical group 0.000 claims 8
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 7
- 201000001320 Atherosclerosis Diseases 0.000 claims 6
- 208000024172 Cardiovascular disease Diseases 0.000 claims 6
- 206010048768 Dermatosis Diseases 0.000 claims 6
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 6
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 6
- 208000032928 Dyslipidaemia Diseases 0.000 claims 6
- 208000002705 Glucose Intolerance Diseases 0.000 claims 6
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 6
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims 6
- 206010020772 Hypertension Diseases 0.000 claims 6
- 208000013016 Hypoglycemia Diseases 0.000 claims 6
- 206010022489 Insulin Resistance Diseases 0.000 claims 6
- 206010023379 Ketoacidosis Diseases 0.000 claims 6
- 208000007976 Ketosis Diseases 0.000 claims 6
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 6
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 208000008589 Obesity Diseases 0.000 claims 6
- 206010030113 Oedema Diseases 0.000 claims 6
- 201000001880 Sexual dysfunction Diseases 0.000 claims 6
- 208000007536 Thrombosis Diseases 0.000 claims 6
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 208000033679 diabetic kidney disease Diseases 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 201000006549 dyspepsia Diseases 0.000 claims 6
- 201000001421 hyperglycemia Diseases 0.000 claims 6
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims 6
- 201000008980 hyperinsulinism Diseases 0.000 claims 6
- 208000020346 hyperlipoproteinemia Diseases 0.000 claims 6
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 6
- 230000002218 hypoglycaemic effect Effects 0.000 claims 6
- 235000020824 obesity Nutrition 0.000 claims 6
- 201000009104 prediabetes syndrome Diseases 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 231100000872 sexual dysfunction Toxicity 0.000 claims 6
- 208000017520 skin disease Diseases 0.000 claims 6
- 208000011580 syndromic disease Diseases 0.000 claims 6
- -1 wherein Chemical group 0.000 claims 6
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 208000024891 symptom Diseases 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 125000006564 (C4-C8) cycloalkyl group Chemical group 0.000 claims 3
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 claims 2
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 claims 2
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 claims 2
- 229940123464 Thiazolidinedione Drugs 0.000 claims 2
- 125000002877 alkyl aryl group Chemical group 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 125000000455 heteroaryl-fused-cycloalkyl group Chemical group 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical group CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims 2
- 229960003105 metformin Drugs 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims 1
- 241000257303 Hymenoptera Species 0.000 claims 1
- 125000005137 alkenylsulfonyl group Chemical group 0.000 claims 1
- 125000004948 alkyl aryl alkyl group Chemical group 0.000 claims 1
- 125000001374 aryl-fused-cycloalkyl group Chemical group 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 0 CC1C(C)(C)*CC1 Chemical compound CC1C(C)(C)*CC1 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19627108P | 2008-10-15 | 2008-10-15 | |
| US61/196,271 | 2008-10-15 | ||
| PCT/US2009/060549 WO2010045258A2 (en) | 2008-10-15 | 2009-10-13 | Spirocyclic gpr40 modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012505896A JP2012505896A (ja) | 2012-03-08 |
| JP2012505896A5 true JP2012505896A5 (OSRAM) | 2012-11-22 |
| JP5551707B2 JP5551707B2 (ja) | 2014-07-16 |
Family
ID=41835743
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011532190A Expired - Fee Related JP5551707B2 (ja) | 2008-10-15 | 2009-10-13 | スピロ環ｇｐｒ４０調節因子 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8748462B2 (OSRAM) |
| EP (1) | EP2358656B1 (OSRAM) |
| JP (1) | JP5551707B2 (OSRAM) |
| AU (1) | AU2009303475B2 (OSRAM) |
| CA (1) | CA2739888C (OSRAM) |
| ES (1) | ES2450567T3 (OSRAM) |
| MX (1) | MX2011003917A (OSRAM) |
| WO (1) | WO2010045258A2 (OSRAM) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2813639A1 (en) | 2010-10-08 | 2012-04-12 | Mochida Pharmaceutical Co. Ltd. | Cyclic amide derivative |
| US20120302566A1 (en) * | 2010-12-01 | 2012-11-29 | Boehringer Ingelheim International Gmbh | Indanyloxydihydrobenzofuranylacetic acids |
| AU2012248629A1 (en) | 2011-04-27 | 2013-11-28 | Mochida Pharmaceutical Co., Ltd. | Novel 3-hydroxyisothiazole 1-oxide derivative |
| CA2834465A1 (en) | 2011-04-28 | 2012-11-01 | Mochida Pharmaceutical Co., Ltd. | Cyclic amide derivative |
| AU2012273007A1 (en) * | 2011-06-23 | 2014-01-30 | Viamet Pharmaceuticals (NC), Inc. | Metalloenzyme inhibitor compounds |
| WO2013128378A1 (en) | 2012-02-28 | 2013-09-06 | Piramal Enterprises Limited | Phenyl alkanoic acid derivatives as gpr agonists |
| US8642585B2 (en) * | 2012-03-26 | 2014-02-04 | Boehringer Ingelheim International Gmbh | Indanyloxydihydrobenzofuranylacetic acids |
| US8809376B2 (en) | 2012-04-30 | 2014-08-19 | Boehringer Ingelheim International Gmbh | Indanyloxydihydrobenzofuranylacetic acids |
| MX2014013865A (es) * | 2012-05-17 | 2015-05-07 | Genentech Inc | Proceso para elaborar compuestos de ciclopentilpirimidina hidroxilada. |
| CA2878625A1 (en) | 2012-07-11 | 2014-01-16 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
| CA2880901A1 (en) | 2012-08-02 | 2014-02-06 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| WO2014086712A1 (en) | 2012-12-07 | 2014-06-12 | Boehringer Ingelheim International Gmbh | New indanyloxydihydrobenzofuranylacetic acids |
| RU2015140066A (ru) | 2013-02-22 | 2017-03-30 | Мерк Шарп И Доум Корп. | Противодиабетические бициклические соединения |
| WO2014170842A2 (en) | 2013-04-17 | 2014-10-23 | Piramal Enterprises Limited | Substituted alkyl carboxylic acid derivatives as gpr agonists |
| JP5975081B2 (ja) | 2013-09-30 | 2016-08-23 | ダイキン工業株式会社 | 含フッ素ビアリール化合物の製造方法 |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| AP2016009176A0 (en) | 2013-11-14 | 2016-04-30 | Cadila Healthcare Ltd | Novel heterocyclic compounds |
| ES2747973T3 (es) | 2013-11-15 | 2020-03-12 | Merck Sharp & Dohme | Compuestos tricíclicos antidiabéticos |
| US9957219B2 (en) | 2013-12-04 | 2018-05-01 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| WO2015089809A1 (en) | 2013-12-19 | 2015-06-25 | Merck Sharp & Dohme Corp. | Antidiabetic substituted heteroaryl compounds |
| US10059667B2 (en) | 2014-02-06 | 2018-08-28 | Merck Sharp & Dohme Corp. | Antidiabetic compounds |
| CN105001212B (zh) * | 2014-04-16 | 2018-01-16 | 江苏柯菲平医药股份有限公司 | 稠环化合物及其制备方法和应用 |
| WO2015176267A1 (en) | 2014-05-22 | 2015-11-26 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| US10968193B2 (en) | 2014-08-08 | 2021-04-06 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| WO2016019587A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | [7, 6]-fused bicyclic antidiabetic compounds |
| WO2016022446A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | [5,6]-fused bicyclic antidiabetic compounds |
| WO2016022448A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| WO2017172505A1 (en) | 2016-03-29 | 2017-10-05 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| WO2018118670A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
| US10919859B2 (en) | 2017-01-26 | 2021-02-16 | Boehringer Ingelheim International Gmbh | Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof |
| US10913720B2 (en) | 2017-01-26 | 2021-02-09 | Boehringer Ingelheim International Gmbh | Benzyloxypyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof |
| CN110248929B (zh) | 2017-01-26 | 2023-05-12 | 勃林格殷格翰国际有限公司 | 苄基氨基吡嗪基环丙烷甲酸、其药物组合物和用途 |
| US10603317B2 (en) | 2017-01-26 | 2020-03-31 | Boehringer Ingelheim International Gmbh | Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof |
| CN110300755B (zh) | 2017-02-08 | 2022-10-04 | 勃林格殷格翰国际有限公司 | 茚满基氨基氮杂二氢苯并呋喃乙酸、用于治疗糖尿病的药物组合物 |
| AR111199A1 (es) | 2017-03-31 | 2019-06-12 | Takeda Pharmaceuticals Co | Compuesto aromático agonista de gpr40 |
| US11225471B2 (en) | 2017-11-16 | 2022-01-18 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| CN111712494A (zh) | 2018-02-13 | 2020-09-25 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
| US20210017174A1 (en) | 2018-03-07 | 2021-01-21 | Bayer Aktiengesellschaft | Identification and use of erk5 inhibitor |
| EP4600247A3 (en) | 2018-04-19 | 2025-11-19 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| KR20230159715A (ko) | 2018-07-13 | 2023-11-21 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| AU2019366355B2 (en) | 2018-10-24 | 2022-10-13 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| CN112010881B (zh) * | 2019-05-30 | 2021-09-03 | 中国科学院兰州化学物理研究所 | 一种烯基硼化合物及其制备方法与应用 |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE305216B (OSRAM) * | 1965-09-17 | 1968-10-21 | Astra Apotekarnes Kem Fab | |
| FR2359135A1 (fr) | 1976-07-22 | 1978-02-17 | Hexachimie | Nouvelles phenoxyhydroxypropylamines, procede pour les preparer et leur application en therapeutique |
| US4760089A (en) * | 1985-09-09 | 1988-07-26 | Smithkline Beckman Corporation | Irreversible dopamine-β-hydroxylase inhibitors |
| DK303887A (da) | 1986-06-19 | 1987-12-20 | Smithkline Beckman Corp | Dopamin-beta-hydroxylaseinhibitorer og fremgangsmaade til fremstilling deraf |
| GB8917069D0 (en) | 1989-07-26 | 1989-09-13 | Merck Sharp & Dohme | Therapeutic agents |
| DE4019307A1 (de) * | 1990-06-16 | 1991-12-19 | Bayer Ag | 2-methoximinocarbonsaeureester |
| AU668181B2 (en) | 1992-05-20 | 1996-04-26 | Merck & Co., Inc. | Ester derivatives of 4-aza-steroids |
| EP0641204B1 (en) | 1992-05-20 | 2000-08-16 | Merck & Co. Inc. | 17-ethers and thioethers of 4-aza-steroids |
| DE4241632A1 (de) | 1992-12-10 | 1994-06-16 | Thomae Gmbh Dr K | Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| AU7006094A (en) | 1993-06-30 | 1995-01-24 | Wellcome Foundation Limited, The | Anti-atherosclerotic diaryl compounds |
| US5463063A (en) | 1993-07-02 | 1995-10-31 | Celgene Corporation | Ring closure of N-phthaloylglutamines |
| US6037367A (en) * | 1995-07-14 | 2000-03-14 | Smithkline Beecham Corporation | Substituted-pent-4-ynoic acids |
| US5795900A (en) | 1995-10-03 | 1998-08-18 | Abbott Laboratories | Symmetrical bis-heteroaryl-methoxy-phenylalkyl carboxylates as inhibitors of leukotriene biosynthesis |
| JPH10316641A (ja) | 1997-03-14 | 1998-12-02 | Sankyo Co Ltd | カルボン酸誘導体 |
| WO1999011255A1 (en) | 1997-08-28 | 1999-03-11 | Ono Pharmaceutical Co., Ltd. | Peroxisome proliferator-activated receptor controllers |
| US6645939B1 (en) * | 1997-11-24 | 2003-11-11 | Merck & Co., Inc. | Substituted β-alanine derivatives as cell adhesion inhibitors |
| US6506757B1 (en) * | 1998-03-10 | 2003-01-14 | Ono Pharmaceutical Co., Ltd. | Carboxylic acid derivatives and drugs containing the same as the active ingredient |
| DE19941567A1 (de) | 1998-09-05 | 2000-04-20 | Merck Patent Gmbh | Neue flüssigkristalline Verbindungen |
| AU3958200A (en) | 1999-04-20 | 2000-11-02 | Novo Nordisk A/S | New compounds, their preparation and use |
| WO2000068223A1 (en) * | 1999-05-05 | 2000-11-16 | Aventis Pharma Limited | Ureas and their use as cell adhesion modulators |
| GB9914977D0 (en) | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
| GB9927056D0 (en) | 1999-11-17 | 2000-01-12 | Karobio Ab | Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders |
| US6677473B1 (en) | 1999-11-19 | 2004-01-13 | Corvas International Inc | Plasminogen activator inhibitor antagonists |
| JP2001242165A (ja) | 2000-02-25 | 2001-09-07 | Dai Ichi Seiyaku Co Ltd | 採血用試薬 |
| JP2002003368A (ja) | 2000-06-23 | 2002-01-09 | Saitama Daiichi Seiyaku Kk | 経皮吸収又は経粘膜吸収用の製剤 |
| GB0031107D0 (en) | 2000-12-20 | 2001-01-31 | Glaxo Group Ltd | Chemical compounds |
| US6906046B2 (en) | 2000-12-22 | 2005-06-14 | Celltech R & D Inc. | Pharmaceutical uses and synthesis of benzobicyclooctanes |
| GB0031527D0 (en) | 2000-12-22 | 2001-02-07 | Smithkline Beecham Plc | New use |
| ATE433964T1 (de) | 2000-12-28 | 2009-07-15 | Takeda Pharmaceutical | Alkansäurederivate, verfahren zu deren herstellung und deren verwendung |
| TWI311133B (en) | 2001-04-20 | 2009-06-21 | Eisai R&D Man Co Ltd | Carboxylic acid derivativeand the salt thereof |
| SK14922003A3 (sk) | 2001-06-07 | 2005-04-01 | Eli Lilly And Company | Modulátory receptorov aktivovaných proliferátormi peroxizómov (PPAR) |
| EP1481965B1 (en) * | 2002-02-07 | 2015-07-29 | Hitoshi Endo | Aromatic amino acid derivatives and medicinal compositions |
| EP1479768B1 (en) * | 2002-02-14 | 2010-04-28 | Takeda Pharmaceutical Company Limited | Novel screening method |
| US20030207924A1 (en) | 2002-03-07 | 2003-11-06 | Xue-Min Cheng | Compounds that modulate PPAR activity and methods of preparation |
| US6875780B2 (en) * | 2002-04-05 | 2005-04-05 | Warner-Lambert Company | Compounds that modulate PPAR activity and methods for their preparation |
| AU2003241173A1 (en) | 2002-05-24 | 2003-12-12 | Takeda Pharmaceutical Company Limited | 1,2-azole derivatives with hypoglycemic and hypolipidemic activity |
| GB0214149D0 (en) | 2002-06-19 | 2002-07-31 | Glaxo Group Ltd | Chemical compounds |
| US7553867B2 (en) | 2002-09-06 | 2009-06-30 | Takeda Pharmaceutical Company Limited | Furan or thiophene derivative and medicinal use thereof |
| US7960369B2 (en) | 2002-11-08 | 2011-06-14 | Takeda Pharmaceutical Company Limited | Receptor function regulator |
| US6906406B2 (en) * | 2002-12-19 | 2005-06-14 | Freescale Semiconductor, Inc. | Multiple dice package |
| CA2521175A1 (en) | 2003-04-07 | 2004-10-28 | Kalypsys, Inc. | Para-sulfonyl substituted phenyl compounds as modulators of ppars |
| JP4805552B2 (ja) * | 2003-05-30 | 2011-11-02 | 武田薬品工業株式会社 | 縮合環化合物 |
| EP1630152A4 (en) * | 2003-05-30 | 2009-09-23 | Takeda Pharmaceutical | CONDENSED CYCLIC COMPOUND |
| US7834013B2 (en) * | 2003-11-19 | 2010-11-16 | Glaxosmithkline Llc | Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to GPR40 |
| CA2547198A1 (en) | 2003-12-17 | 2005-06-30 | Merck & Co., Inc. | (3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists |
| WO2005063729A1 (en) | 2003-12-25 | 2005-07-14 | Takeda Pharmaceutical Company Limited | 3-(4-benzyloxyphenyl)propanoic acid derivatives |
| EP1698624B1 (en) | 2003-12-26 | 2012-06-27 | Takeda Pharmaceutical Company Limited | Phenylpropanoic acid derivatives |
| WO2005080367A1 (en) * | 2004-02-12 | 2005-09-01 | Pharmagene Laboratories Limited | Ep2 receptor agonists |
| BRPI0508098A (pt) * | 2004-02-27 | 2007-07-17 | Amgen Inc | compostos, composições farmacêuticas e métodos para uso no tratamento de distúrbios metabólicos |
| CA2560111A1 (en) | 2004-03-15 | 2005-09-22 | Takeda Pharmaceutical Company Limited | Aminophenylpropanoic acid derivative |
| EP1731505B1 (en) | 2004-03-30 | 2015-01-14 | Takeda Pharmaceutical Company Limited | Alkoxyphenylpropanoic acid derivatives |
| JP2007269630A (ja) | 2004-06-23 | 2007-10-18 | Toudai Tlo Ltd | インスリン分泌促進剤 |
| US20060003344A1 (en) * | 2004-06-30 | 2006-01-05 | Pfizer Inc. | Methods related to a single nucleotide polymorphism of the G protein coupled receptor, GPR40 |
| JP2007284350A (ja) | 2004-07-27 | 2007-11-01 | Takeda Chem Ind Ltd | 糖尿病治療剤 |
| US20080090865A1 (en) | 2005-01-28 | 2008-04-17 | Min Ge | Antidiabetic Bicyclic Compounds |
| US7759493B2 (en) | 2005-01-31 | 2010-07-20 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| US7465804B2 (en) * | 2005-05-20 | 2008-12-16 | Amgen Inc. | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders |
| WO2007008541A2 (en) | 2005-07-08 | 2007-01-18 | Kalypsys, Inc. | Cellular cholesterol absorption modifiers |
| JP5084503B2 (ja) | 2005-07-29 | 2012-11-28 | 武田薬品工業株式会社 | シクロプロパンカルボン酸化合物 |
| EP1924546A1 (en) * | 2005-09-14 | 2008-05-28 | Amgen, Inc | Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders |
| WO2007049050A2 (en) | 2005-10-27 | 2007-05-03 | Heptahelix Ab | Modulators of gpr40 for the treatment of diabetes |
| JP2009530281A (ja) * | 2006-03-14 | 2009-08-27 | アムジエン・インコーポレーテツド | 代謝障害の治療に有用である二環式カルボン酸誘導体 |
| TW200815377A (en) | 2006-04-24 | 2008-04-01 | Astellas Pharma Inc | Oxadiazolidinedione compound |
| DE102006021878A1 (de) | 2006-05-11 | 2007-11-15 | Sanofi-Aventis | Phenylamino-benzoxazol substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| DE102006021874B4 (de) | 2006-05-11 | 2008-03-27 | Sanofi-Aventis | 4,5-Diphenyl-pyrimidinyl-amino substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| DE102006021872B4 (de) | 2006-05-11 | 2008-04-17 | Sanofi-Aventis | 4,5-Diphenyl-pyrimidinyl-oxy oder -mercapto substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| WO2007136572A2 (en) * | 2006-05-15 | 2007-11-29 | Merck & Co., Inc. | Antidiabetic bicyclic compounds |
| JP4401428B2 (ja) | 2006-06-27 | 2010-01-20 | 武田薬品工業株式会社 | 縮合環化合物 |
| EP2061760A1 (en) * | 2006-09-07 | 2009-05-27 | Amgen, Inc | Benzo-fused compounds for use in treating metabolic disorders |
| WO2008030520A1 (en) * | 2006-09-07 | 2008-03-13 | Amgen Inc. | Heterocyclic gpr40 modulators |
| WO2008054675A2 (en) | 2006-10-31 | 2008-05-08 | Merck & Co., Inc. | Antidiabetic bicyclic compounds |
| JP2010524932A (ja) | 2007-04-16 | 2010-07-22 | アムジエン・インコーポレーテツド | 置換ビフェニルフェノキシ−、チオフェニル−及びアミノフェニルプロパン酸ｇｐｒ４０調節物質 |
| KR20100090249A (ko) * | 2007-10-10 | 2010-08-13 | 암젠 인크 | 치환된 비페닐 ｇｒｐ４０ 조절제 |
-
2009
- 2009-10-13 ES ES09741123.5T patent/ES2450567T3/es active Active
- 2009-10-13 JP JP2011532190A patent/JP5551707B2/ja not_active Expired - Fee Related
- 2009-10-13 AU AU2009303475A patent/AU2009303475B2/en not_active Ceased
- 2009-10-13 EP EP09741123.5A patent/EP2358656B1/en active Active
- 2009-10-13 CA CA2739888A patent/CA2739888C/en not_active Expired - Fee Related
- 2009-10-13 WO PCT/US2009/060549 patent/WO2010045258A2/en not_active Ceased
- 2009-10-13 US US13/119,951 patent/US8748462B2/en active Active
- 2009-10-13 MX MX2011003917A patent/MX2011003917A/es active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012505896A5 (OSRAM) | ||
| JP2011500562A5 (OSRAM) | ||
| CN111848614B (zh) | 吡啶酮衍生物及抗流感病毒药物组合物 | |
| Darwish et al. | Design, synthesis, and biological evaluation of novel thiazolidinediones as PPARγ/FFAR1 dual agonists | |
| CN1069901C (zh) | N－苄基二氧代噻唑烷基苯甲酰胺衍生物及其制造方法 | |
| CA2739888C (en) | Spirocyclic gpr40 modulators | |
| CA2662305A1 (en) | Heterocyclic gpr40 modulators | |
| JP2009530281A5 (OSRAM) | ||
| JP2007500720A5 (OSRAM) | ||
| JP2019069940A (ja) | スルファモイル−アリールアミド及びｂ型肝炎の治療のための薬剤としてのその使用 | |
| Zhu et al. | N 2-Selective iodofunctionalization of olefins with NH-1, 2, 3-triazoles to provide N 2-alkyl-substituted 1, 2, 3-triazoles | |
| WO2007126043A1 (ja) | チアゾール環を含むカルボン酸誘導体の医薬用途 | |
| JP2009525275A (ja) | 多環式１，２，３，４−テトラヒドロ−イソキノリン誘導体およびｐｐａｒモジュレーターとしてのそれらを含む組成物 | |
| RU2014138894A (ru) | Производные фенилалкановой кислоты в качестве агонистов gpr | |
| KR20100098534A (ko) | 바이러스 폴리머라제 억제제 | |
| CA2782727A1 (en) | 2-pyridone compounds | |
| JP2017537111A (ja) | ヘテロ環式誘導体およびその使用 | |
| JP2018528159A (ja) | 芳香族スルホンアミド誘導体 | |
| JP2005532392A5 (OSRAM) | ||
| CN109996797A (zh) | 作为乳酸脱氢酶的抑制剂的1h-吡唑-1-基-噻唑及其使用方法 | |
| JP2025538389A (ja) | グルカゴン様ペプチド１受容体アゴニスト | |
| EP4615573A1 (en) | Glucagon-like peptide 1 receptor agonists | |
| WO2014180165A1 (zh) | 苯并异噻唑类化合物及在制备抗精神分裂症药物中的应用 | |
| HK1040249A1 (en) | Propanolamine derivatives substituted with heterocyclic compounds, methods for their production, pharmaceutical composition containing said compounds and the use thereof | |
| Kallemeyn et al. | Development of a large-scale route to glecaprevir: Synthesis of the macrocycle via intramolecular etherification |